THBD and leukemia: Yamakawa et al. reported increased use of recombinant thrombomodulin throughout the study period and attributed the decreased mortality both to changes in anticoagulant treatment in patients with DIC and to important advances in treatment of the diseases associated with DIC, particularly sepsis and leukaemia.